SI-BONE, Inc. (SIBN) Stock Price & Analysis
SI-BONE, Inc. (SIBN) closed at USD 21.56 on Thursday, October 22, 2026, up 3.55% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 20.82; the Oct 22, 2026 session ranged USD 20.93–21.73 on volume of 526,132 shares. Market capitalization is $966.29M, with a 52-week range of USD 11.48–21.89 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:25 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SIBN.md
Key facts (SIBN)
- Last four reported quarters (through Jun 30, 2026): revenue $214M, net income -$14.6M (-6.9% margin), free cash flow -$4.4M (SEC filings).
- 1 of 80 tracked superinvestors hold SIBN (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.67 on a 1–5 scale) (9 analysts), mean target USD 25.44 (range 20–32).
- Total return with dividends: 1Y +39.7% vs S&P 500 +14.9%; 5Y -2.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD -0.13, revenue estimate $55.3M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SIBN)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $90.2M | $106M | $139M | $167M | $201M | $214M |
| Gross profit | $79.7M | $90.7M | $109M | $132M | $160M | — |
| Operating income | -$51.7M | -$59.6M | -$46.9M | -$35.2M | -$22.3M | -$17.7M |
| Net income | -$56.6M | -$61.3M | -$43.3M | -$30.9M | -$18.9M | -$14.6M |
| EPS (diluted) | -$1.71 | -$1.79 | -$1.13 | -$0.75 | -$0.44 | — |
| Free cash flow | -$45.9M | -$51.2M | -$26.5M | -$22.9M | -$9.1M | -$4.4M |
| Gross margin | 88.4% | 85.2% | 78.8% | 79.0% | 79.6% | — |
| Operating margin | -57.3% | -56.0% | -33.8% | -21.1% | -11.1% | -8.3% |
| Net margin | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% | -6.9% |
| Revenue growth | +22.8% | +18.0% | +30.5% | +20.4% | +20.2% | — |
| Cash + short-term investments | $141M | $84.6M | $156M | $142M | $139M | — |
| Total debt | $35.0M | $35.2M | $36.1M | $35.5M | $35.6M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SIBN)
P/S 4.5x · EV/Sales 4.0x · P/B 5.3x · FCF yield -0.45% · Earnings yield -1.51% · Net cash $106M · EV $860M
Superinvestors (SEC 13F-HR, Q2 2026) (SIBN)
1 of 80 tracked investors hold SIBN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.02% | $12.5M | Added +20.4% |
Analysts (SIBN)
Consensus Buy (mean 1.67 on a 1–5 scale), 9 analysts; mean target USD 25.44 (low 20, high 32).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Truist Securities | Target raised | Buy | $23 → $25 |
| 2026-08-04 | UBS | Target raised | Buy | $24 → $25 |
| 2026-08-04 | Truist Securities | Target raised | Buy | $21 → $23 |
| 2026-08-04 | TD Cowen | Target raised | Buy | $18 → $20 |
| 2026-07-28 | UBS | Initiated | Buy | $24 |
| 2026-07-16 | Truist Securities | Target raised | Buy | $18 → $21 |
Total return (dividends reinvested) (SIBN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +39.7% | -2.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +39.9% | -0.5% |
| Volatility (annualized) | 47.8% | 54.5% |
| Max drawdown | -45.8% (Jan 2026→May 2026) | -57.8% (Jun 2023→Jun 2024) |
SIBN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.13 | $-0.13 | -1.4% | $55.3M | 8 |
| Next quarter (ends Dec 2026) | $-0.07 | $-0.05 | +54.3% | $68.2M | 8 |
| Current fiscal year (ends Dec 2026) | $-0.40 | $-0.43 | -7.3% | $232.1M | 8 |
| Next fiscal year (ends Dec 2027) | $-0.33 | $-0.35 | -6.2% | $268.4M | 8 |
Key Statistics (as of October 23, 2026 at 09:25 UTC)
| Price | USD 21.56 |
|---|---|
| Change | ▲ 3.55% (up) |
| Previous Close | USD 20.82 |
| Open | USD 20.93 |
| Day Range | USD 20.93 – 21.73 |
| 52-Week Range | USD 11.48 – 21.89 |
| Volume | 526,132 shares |
| Market Cap | $966.29M |
| Exchange | NGM |
Technical Analysis (SIBN)
Nexqual's technical model rates SIBN "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:25 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.08 (overbought) |
| vs SMA50 | Above (USD 19.12) |
| MACD | 0.54 (positive) |
Analyst Ratings (SIBN)
Wall Street analysts rate SIBN "Buy" based on 9 analysts, with a mean price target of USD 25.44 (range USD 20–32), per Nexqual as of October 23, 2026 at 09:25 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 25.44 |
| High Target | USD 32 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (SIBN)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $55.31M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.09 vs est -0.15 ▲ beat |
| 2026-03-31 | USD -0.1 vs est -0.19 ▲ beat |
| 2025-12-31 | USD -0.04 vs est -0.13 ▲ beat |
| 2025-09-30 | USD -0.11 vs est -0.17 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financials & Fundamentals (SIBN)
| Total Revenue | $213.60M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +15.20% |
| Gross Margin | +79.53% |
| Operating Margin | -8.58% |
| Profit Margin | -6.85% |
| ROE | -8.30% |
| Debt / Equity | 0.23 |
| Current Ratio | 9.15 |
| Total Cash | $145.94M |
| Total Debt | $42.80M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$4.39M (-2.1% of revenue) |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financial Health Score (SIBN)
Nexqual rates SI-BONE, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:25 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 80%, operating -9% (last 12 months) |
| Balance Sheet | Strong — $141M cash and investments vs $36M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$4M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -8%, ROA -4.6% |
Ownership (SIBN)
| Insider Ownership | +3.25% |
|---|---|
| Institutional Ownership | +109.51% |
| Shares Outstanding | 44.82M |
| Float | 40.02M |
| Short % of Float | +13.30% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Leadership (SIBN)
SI-BONE, Inc. is led by Laura A. Francis, CEO & Director, per Nexqual as of October 23, 2026 at 09:25 UTC.
| CEO & Director | Laura A. Francis |
|---|---|
| Executive Chairman | Jeffrey W. Dunn |
| COO & CFO | Anshul Maheshwari |
| Senior VP of Engineering & CTO | Scott A. Yerby |
| Vice President of Product & Marketing | Ian Bailey |
Major Backers & Investors (SIBN)
Notable institutional backers of SI-BONE, Inc. include First Light Asset Management, LLC, Cadian Capital Management, LP, American Century Companies Inc, according to Nexqual as of October 23, 2026 at 09:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Light Asset Management, LLC | 18.33% |
| Cadian Capital Management, LP | 7.55% |
| American Century Companies Inc | 5.66% |
| Brown Advisory Inc. | 4.68% |
| Granahan Investment Management LLC | 4.35% |
| Impax Asset Management Group plc | 3.21% |
| IMPAX FUNDS SERIES TRUST I-Impax Small Cap Fund | 3.21% |
| Gilder Gagnon Howe & Co LLC | 2.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.29% |
| Vanguard Group | 4.15% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVCR | NovoCure Limited | USD 15.1 | ▼ 3.14% |
| BFLY | Butterfly Network, Inc. | USD 6.81 | ▼ 4.08% |
| ESTA | Establishment Labs Holdings Inc | USD 63.52 | ▲ 1.99% |
| ALMR | Alamar Biosciences, Inc. | USD 29.72 | ▼ 5.5% |
| INSP | Inspire Medical Systems, Inc. | USD 72.66 | ▲ 2.24% |
| AXGN | AxoGen, Inc. | USD 36.68 | ▲ 0.55% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:25 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt